LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
申请人:Cayman Chemical Company, Incorporated
公开号:EP3235817A1
公开(公告)日:2017-10-25
Disclosed herein are compounds of formula (I)
wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
此处公开的是式 (I) 化合物
其中 L1、L2、L3、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式(I)化合物是 EP4 激动剂,可用于治疗青光眼、骨质疏松症、骨折、牙周骨质流失、骨科植入物、脱发、神经性疼痛及相关疾病。还描述了治疗条件或疾病的药物组合物和方法。